Jump Into an All-New Mickey & Friends Adventure with Disney Illusion Island on July 28
9.2.2023 17:00:00 EET | Business Wire | Press release
Embark on a brand-new adventure with Disney Mickey Mouse’s triumphant return to video games – and this time he’s bringing a few friends! Today, Disney, in collaboration with developer Dlala Studios, revealed that Disney Illusion Island , an upcoming local cooperative 2D platform adventure video game for up to four players, will debut exclusively for Nintendo Switch™ on July 28, 2023. Additionally, pre-orders for Disney Illusion Island are available for $39.99 in Nintendo eShop and at retail, beginning today.
“Fans are in for a treat with the upcoming launch of the whimsical cartoon-like experience offered by Disney Illusion Island,” said Luigi Priore, VP, Disney, Pixar and 20th Century Games. “We’re thrilled to work with developer Dlala Studios as they expand upon the Mickey & Friends world with a new and original storyline, engaging gameplay and delightful hand-drawn art style.”
Join Mickey Mouse, Minnie Mouse, Donald Duck and Goofy and set off on a perilous quest to explore the colorfully hand-crafted and yet mysterious island of Monoth in an escapade to recover three magical Tomes – powerful books used to protect the island. Featuring the voice actors of Mickey, Minnie, Donald, and Goofy and an original orchestral score, players can immerse themselves in a solo adventure or team up with up to three friends in local co-op to use special team skills such as Rope Drop, Leap Frog, and a heart gifting Hug to save the island. Discover rich biomes and never-before-seen environments, meet strange yet intriguing characters, and uncover hidden secrets galore!
But the journey will not be easy, and with intrigue afoot, not everything is what it seems on “Illusion Island.”
“Words cannot express how excited we are for players to embrace the Dlala-spin on this brand-new experience for Mickey Mouse, Minnie Mouse, Donald Duck and Goofy,” said AJ Grand-Scrutton, Lead Developer, Dlala Studios. “It has been an incredible honor working on this title and we hope that Nintendo Switch players and Disney fans worldwide love playing it as much as we've loved creating it.”
Disney Illusion Island will be available for $39.99 and will debut worldwide exclusively for Nintendo Switch on July 28, 2023.
For more information about Disney Illusion Island: https://games.disney.com/disney-illusion-island
To watch the latest trailer: https://www.youtube.com/watch?v=Ll9zSkf4Cfw
For Disney Illusion Island assets: https://drive.google.com/drive/folders/1sVurQkkRn_Tq94FDsbBipvWoP3-ssuhe?usp=sharing
For more updates on Disney Illusion Island, please follow us on social below:
About Dlala Studios
Dlala Studios are the creators of Battletoads (2020), and have previously worked on award-winning titles such as Sea of Thieves, The Escapists, and Lost Words: Beyond The Page. The Essex-based studio celebrated their 10th anniversary in 2022, and are currently developing Disney Illusion Island for the Nintendo Switch.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005020/en/
Contact information
MEDIA CONTACT
Disney Consumer Products, Games and Publishing
Dashaun Gasque
Communications Manager
DASHAUN.GASQUE@DISNEY.COM
Dylan Quintero
Senior Specialist, Communications
DYLAN.QUINTERO@DISNEY.COM
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom